The DOI matches its Crossref record; 202 of the 202 references it cites were found in a registry or an index.
The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Abstract
The Keap1–Nrf2–ARE ((Kelch‐like ECH‐Associating protein 1) nuclear factor erythroid 2 related factor 2‐antioxidant response element) pathway is one of the most important defense mechanisms against oxidative and/or electrophilic stresses, and it is closely associated with inflammatory diseases, including cancer, neurodegenerative diseases, cardiovascular diseases, and aging. In recent years, progress has been made in strategies aimed at modulating the Keap1–Nrf2–ARE pathway. The Nrf2 activator DMF (Dimethylfumarates) has been approved by the FDA as a new first‐line oral drug to treat patients with relapsing forms of multiple sclerosis, while a phase 3 study of another promising candidate, CDDO‐Me, was terminated for safety reasons. Directly inhibiting Keap1–Nrf2 protein–protein interactions as a novel Nrf2‐modulating strategy has many advantages over using electrophilic Nrf2 activators. The development of Keap1–Nrf2 protein–protein interaction inhibitors has become a topic of intense research, and potent inhibitors of this target have been identified. In addition, inhibiting Nrf2 activity has attracted an increasing amount of attention because it may provide an alternative cancer therapy. This review summarizes the molecular mechanisms and biological functions of the Keap1–Nrf2–ARE system. The main focus of this review is on recent progress in studies of agents that target the Keap1–Nrf2–ARE pathway and the therapeutic applications of such agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Malhotra, D., Thimmulappa, R., Navas-Acien, A., Sandford, A., Elliott, M., Singh, A., Chen, L., Zhuang, X., Hogg, J., Pare, P., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200803-380oc · Cited by 357
RetractedNiture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedINrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis
Niture, S. K., & Jaiswal, A. K. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.114 · Cited by 90
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedOxidants, oxidative stress and the biology of ageing
Finkel, T., & Holbrook, N. J. (2000) · Nature · doi:10.1038/35041687 · Cited by 9,413
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
The Acute Respiratory Distress Syndrome
Matthay, M. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342209 · Cited by 4,923
The Acute Respiratory Distress Syndrome
Ware, L. B., & Matthay, M. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421806 · Cited by 4,666
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Reactive oxygen species have a causal role in multiple forms of insulin resistance
Houstis, N., Rosen, E. D., & Lander, E. S. (2006) · Nature · doi:10.1038/nature04634 · Cited by 2,525
Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2021 · Cited by 2,288
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Zhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
The emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex
Zhang, D. D., Lo, S.-C., Cross, J. V., Templeton, D. J., & Hannink, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10941-10953.2004 · Cited by 1,254
Phosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy
Ichimura, Y., Waguri, S., Sou, Y.-S., Kageyama, S., Hasegawa, J., Ishimura, R., Saito, T., Yang, Y., Kouno, T., Fukutomi, T., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.003 · Cited by 1,205
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011) · Brain · doi:10.1093/brain/awq386 · Cited by 1,155
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Molecular Mechanisms Activating the Nrf2-Keap1 Pathway of Antioxidant Gene Regulation
Kobayashi, M., & Yamamoto, M. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.385 · Cited by 1,076
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067
Chemistry: Chemical con artists foil drug discovery
Baell, J., & Walters, M. A. (2014) · Nature · doi:10.1038/513481a · Cited by 1,043
Huang, H.-C., Nguyen, T., & Pickett, C. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206911200 · Cited by 1,034
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306033 · Cited by 1,030
Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis
Thimmulappa, R. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25790 · Cited by 1,028
The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation
Bryan, H. K., Olayanju, A., Goldring, C. E., & Park, B. K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.016 · Cited by 1,024
Molecular basis of the Keap1–Nrf2 system
Suzuki, T., & Yamamoto, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.006 · Cited by 995
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
Hayes, J. D., & McMahon, M. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 869
Niture, S. K., Khatri, R., & Jaiswal, A. K. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.02.008 · Cited by 868
Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W., & Ting, J. P.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607260103 · Cited by 818
Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T. W., Wasserman, W. W., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq212 · Cited by 794
Small Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759
Furukawa, M., & Xiong, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.162-171.2005 · Cited by 746
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease
Cachofeiro, V., Goicochea, M., de Vinuesa, S. G., Oubiña, P., Lahera, V., & Luño, J. (2008) · Kidney International · doi:10.1038/ki.2008.516 · Cited by 662
Role of NRF2 in Protection Against Hyperoxic Lung Injury in Mice
Cho, H.-Y., Jedlicka, A. E., Reddy, S. P. M., Kensler, T. W., Yamamoto, M., Zhang, L.-Y., & Kleeberger, S. R. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.26.2.4501 · Cited by 659
Offen, D., Gilgun-Sherki, Y., & Melamed, E. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0348-9 · Cited by 638
Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
Lo, S., Li, X., Henzl, M. T., Beamer, L. J., & Hannink, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601243 · Cited by 604
Nrf2 is essential for protection against acute pulmonary injury in mice
Chan, K., & Kan, Y. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12731 · Cited by 574
Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha
Chorley, B. N., Campbell, M. R., Wang, X., Karaca, M., Sambandan, D., Bangura, F., Xue, P., Pi, J., Kleeberger, S. R., & Bell, D. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks409 · Cited by 558
Linking oxidative stress to inflammation: Toll-like receptors
Gill, R., Tsung, A., & Billiar, T. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.01.006 · Cited by 553
Huang, H.-C., Nguyen, T., & Pickett, C. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220418997 · Cited by 539
Cancer Chemoprevention Mechanisms Mediated Through the Keap1–Nrf2 Pathway
Hayes, J. D., McMahon, M., Chowdhry, S., & Dinkova-Kostova, A. T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3221 · Cited by 539
Nrf2, a multi‐organ protector?
Lee, J., Li, J., Johnson, D. A., Stein, T. D., Kraft, A. D., Calkins, M. J., Jakel, R. J., & Johnson, J. A. (2005) · The FASEB Journal · doi:10.1096/fj.04-2591hyp · Cited by 532
Diabetes, oxidative stress and therapeutic strategies
Rochette, L., Zeller, M., Cottin, Y., & Vergely, C. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.05.017 · Cited by 530
Bloom, D. A., & Jaiswal, A. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307633200 · Cited by 525
Katoh, Y., Itoh, K., Yoshida, E., Miyagishi, M., Fukamizu, A., & Yamamoto, M. (2001) · Genes to Cells · doi:10.1046/j.1365-2443.2001.00469.x · Cited by 520
Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview
Itoh, K., Mimura, J., & Yamamoto, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3222 · Cited by 510
Xu, L., Wei, Y., Reboul, J., Vaglio, P., Shin, T.-H., Vidal, M., Elledge, S. J., & Harper, J. W. (2003) · Nature · doi:10.1038/nature01985 · Cited by 495
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M., & Hayes, J. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601119200 · Cited by 485
Nrf2: friend or foe for chemoprevention?
Kensler, T. W., & Wakabayashi, N. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp231 · Cited by 484
Weisberg, S. P., Leibel, R., & Tortoriello, D. V. (2008) · Endocrinology · doi:10.1210/en.2008-0262 · Cited by 480
Two-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism
Tong, K. I., Kobayashi, A., Katsuoka, F., & Yamamoto, M. (2006) · Biological Chemistry · doi:10.1515/bc.2006.164 · Cited by 473
Managing the challenge of chemically reactive metabolites in drug development
Park, B. K., Boobis, A., Clarke, S., Goldring, C. E. P., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 462
Scannevin, R. H., Chollate, S., Jung, M.-Y., Shackett, M., Patel, H., Bista, P., Zeng, W., Ryan, S., Yamamoto, M., Lukashev, M., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.190132 · Cited by 461
Kode, A., Rajendrasozhan, S., Caito, S., Yang, S.-R., Megson, I. L., & Rahman, I. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00361.2007 · Cited by 447
Tong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-07 · Cited by 442
The Nrf2/ARE Pathway as a Potential Therapeutic Target in Neurodegenerative Disease
Calkins, M. J., Johnson, D. A., Townsend, J. A., Vargas, M. R., Dowell, J. A., Williamson, T. P., Kraft, A. D., Lee, J.-M., Li, J., & Johnson, J. A. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2242 · Cited by 438
Nrf2–MafG heterodimers contribute globally to antioxidant and metabolic networks
Hirotsu, Y., Katsuoka, F., Funayama, R., Nagashima, T., Nishida, Y., Nakayama, K., Douglas Engel, J., & Yamamoto, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks827 · Cited by 431
The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase
Pintard, L., Willis, J. H., Willems, A., Johnson, J.-L. F., Srayko, M., Kurz, T., Glaser, S., Mains, P. E., Tyers, M., Bowerman, B., et al. (2003) · Nature · doi:10.1038/nature01959 · Cited by 429
de Vries, H. E., Witte, M., Hondius, D., Rozemuller, A. J. M., Drukarch, B., Hoozemans, J., & van Horssen, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.001 · Cited by 428
Solis, L. M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N. C., Moran, C. A., Corvalan, A. H., Biswal, S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 428
Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405
KEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ
Lee, D.-F., Kuo, H.-P., Liu, M., Chou, C.-K., Xia, W., Du, Y., Shen, J., Chen, C.-T., Huo, L., Hsu, M.-C., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.07.025 · Cited by 399
The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism
Mitsuishi, Y., Motohashi, H., & Yamamoto, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00200 · Cited by 392
The Carboxy-Terminal Neh3 Domain of Nrf2 Is Required for Transcriptional Activation
Nioi, P., Nguyen, T., Sherratt, P. J., & Pickett, C. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10895-10906.2005 · Cited by 381
Baird, L., Llères, D., Swift, S., & Dinkova-Kostova, A. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305687110 · Cited by 380
Iida, K., Itoh, K., Kumagai, Y., Oyasu, R., Hattori, K., Kawai, K., Shimazui, T., Akaza, H., & Yamamoto, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1906 · Cited by 370
The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm
Zipper, L. M., & Mulcahy, R. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206530200 · Cited by 366
Keap1–Nrf2 Signaling: A Target for Cancer Prevention by Sulforaphane
Kensler, T. W., Egner, P. A., Agyeman, A. S., Visvanathan, K., Groopman, J. D., Chen, J.-G., Chen, T.-Y., Fahey, J. W., & Talalay, P. (2012) · Topics in Current Chemistry · doi:10.1007/128_2012_339 · Cited by 361
Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide
Thimmulappa, R. K., Scollick, C., Traore, K., Yates, M., Trush, M. A., Liby, K. T., Sporn, M. B., Yamamoto, M., Kensler, T. W., & Biswal, S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.102 · Cited by 357
The transcription factor NRF2 protects against pulmonary fibrosis
Cho, H.-Y., Reddy, S. P. M., Yamamoto, M., & Kleeberger, S. R. (2004) · The FASEB Journal · doi:10.1096/fj.03-1127fje · Cited by 355
Nrf2‐deficient mice are highly susceptible to cigarette smoke‐induced emphysema
Iizuka, T., Ishii, Y., Itoh, K., Kiwamoto, T., Kimura, T., Matsuno, Y., Morishima, Y., Hegab, A. E., Homma, S., Nomura, A., et al. (2005) · Genes to Cells · doi:10.1111/j.1365-2443.2005.00905.x · Cited by 336
Tang, X., Wang, H., Fan, L., Wu, X., Xin, A., Ren, H., & Wang, X. J. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.008 · Cited by 325
Abed, D. A., Goldstein, M., Albanyan, H., Jin, H., & Hu, L. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.008 · Cited by 319
Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway
Yu, M., Li, H., Liu, Q., Liu, F., Tang, L., Li, C., Yuan, Y., Zhan, Y., Xu, W., Li, W., et al. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.01.014 · Cited by 317
Numazawa, S., Ishikawa, M., Yoshida, A., Tanaka, S., & Yoshida, T. (2003) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00043.2003 · Cited by 317
Sporn, M. B., Liby, K. T., Yore, M. M., Fu, L., Lopchuk, J. M., & Gribble, G. W. (2011) · Journal of Natural Products · doi:10.1021/np100826q · Cited by 312
Wang, X. J., Hayes, J. D., Henderson, C. J., & Wolf, C. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709483104 · Cited by 309
Freigang, S., Ampenberger, F., Spohn, G., Heer, S., Shamshiev, A. T., Kisielow, J., Hersberger, M., Yamamoto, M., Bachmann, M. F., & Kopf, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201041316 · Cited by 300
Suzuki, M., Betsuyaku, T., Ito, Y., Nagai, K., Nasuhara, Y., Kaga, K., Kondo, S., & Nishimura, M. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2007-0424oc · Cited by 286
Suh, N., Wang, Y., Honda, T., Gribble, G. W., Dmitrovsky, E., Hickey, W. F., Maue, R. A., Place, A. E., Porter, D. M., Spinella, M. J., et al. (1999) · PubMed · Cited by 282
Ageing, oxidative stress and cancer: paradigms in parallax
Benz, C. C., & Yau, C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2522 · Cited by 278
Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
Konstantinopoulos, P. A., Spentzos, D., Fountzilas, E., Francoeur, N., Sanisetty, S., Grammatikos, A. P., Hecht, J. L., & Cannistra, S. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4668 · Cited by 270
Yates, M. S., Tran, Q. T., Dolan, P. M., Osburn, W. O., Shin, S., McCulloch, C. C., Silkworth, J. B., Taguchi, K., Yamamoto, M., Williams, C. R., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp100 · Cited by 269
Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
Cleasby, A., Yon, J., Day, P. J., Richardson, C., Tickle, I. J., Williams, P. A., Callahan, J. F., Carr, R., Concha, N., Kerns, J. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098896 · Cited by 258
Idiosyncratic Drug Reactions: Past, Present, and Future
Uetrecht, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700186p · Cited by 257
Nuclear factor erythroid 2-related factor 2 protects against beta amyloid
Kanninen, K., Malm, T. M., Jyrkkänen, H.-K., Goldsteins, G., Keksa-Goldsteine, V., Tanila, H., Yamamoto, M., Ylä-Herttuala, S., Levonen, A.-L., & Koistinaho, J. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.07.010 · Cited by 255
Jiang, Z.-Y., Lu, M.-C., Xu, L., Yang, T.-T., Xi, M.-Y., Xu, X.-L., Guo, X.-K., Zhang, X.-J., You, Q.-D., & Sun, H.-P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5000529 · Cited by 252
Self-citationNrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes
He, X., Kan, H., Cai, L., & Ma, Q. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.10.007 · Cited by 249
Marcotte, D., Zeng, W., Hus, J.-C., McKenzie, A., Hession, C., Jin, P., Bergeron, C., Lugovskoy, A., Enyedy, I., Cuervo, H., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.019 · Cited by 239
Nrf2 protects against airway disorders
Cho, H.-Y., & Kleeberger, S. R. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.024 · Cited by 239
He, H.-J. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i5.94 · Cited by 236
Xue, M., Qian, Q., Adaikalakoteswari, A., Rabbani, N., Babaei-Jadidi, R., & Thornalley, P. J. (2008) · Diabetes · doi:10.2337/db06-1003 · Cited by 235
Activation of the Nrf2–ARE signaling pathway: a promising strategy in cancer prevention
Giudice, A., & Montella, M. (2006) · BioEssays · doi:10.1002/bies.20359 · Cited by 234
Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD
Pergola, P. E., Krauth, M., Huff, J. W., Ferguson, D. A., Ruiz, S., Meyer, C. J., & Warnock, D. G. (2011) · American Journal of Nephrology · doi:10.1159/000327599 · Cited by 233
Olayanju, A., Copple, I. M., Bryan, H. K., Edge, G. T., Sison, R. L., Wong, M. W., Lai, Z.-Q., Lin, Z.-X., Dunn, K., Sanderson, C. M., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.003 · Cited by 232
Ogura, T., Tong, K. I., Mio, K., Maruyama, Y., Kurokawa, H., Sato, C., & Yamamoto, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914036107 · Cited by 229
NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease
Boutten, A., Goven, D., Artaud-Macari, E., Boczkowski, J., & Bonay, M. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.02.006 · Cited by 221
Boettler, U., Sommerfeld, K., Volz, N., Pahlke, G., Teller, N., Somoza, V., Lang, R., Hofmann, T., & Marko, D. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.03.011 · Cited by 220
BRG1 Interacts with Nrf2 To Selectively Mediate HO-1 Induction in Response to Oxidative Stress
Zhang, J., Ohta, T., Maruyama, A., Hosoya, T., Nishikawa, K., Maher, J. M., Shibahara, S., Itoh, K., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00700-06 · Cited by 213
A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity
Nioi, P., & Nguyen, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.051 · Cited by 212
Molecular cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and apoptosis
Stępkowski, T. M., & Kruszewski, M. K. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.033 · Cited by 211
Small molecule modulators of antioxidant response pathway
Hur, W., & Gray, N. S. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.12.009 · Cited by 211
Rachakonda, G., Xiong, Y., Sekhar, K. R., Stamer, S. L., Liebler, D. C., & Freeman, M. L. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700302s · Cited by 207
Honda, T., Rounds, B. V., Gribble, G. W., Suh, N., Wang, Y., & Sporn, M. B. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00479-x · Cited by 204
Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction
Hu, L., Magesh, S., Chen, L., Wang, L., Lewis, T. A., Chen, Y., Khodier, C., Inoyama, D., Beamer, L. J., Emge, T. J., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.013 · Cited by 200
Lo, S.-C., & Hannink, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606539200 · Cited by 199
Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema
Goven, D., Boutten, A., Lecon-Malas, V, Marchal-Somme, J., Amara, N., Crestani, B., Fournier, M., Leseche, G., Soler, P., Boczkowski, J., et al. (2008) · Thorax · doi:10.1136/thx.2007.091181 · Cited by 195
Bagul, P. K., Middela, H., Matapally, S., Padiya, R., Bastia, T., Madhusudana, K., Reddy, B. R., Chakravarty, S., & Banerjee, S. K. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.05.003 · Cited by 193
Hu, R., Saw, C. L.-L., Yu, R., & Kong, A.-N. T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3276 · Cited by 187
The transcription factor NF‐E2‐related Factor 2 (Nrf2): a protooncogene?
Shelton, P., & Jaiswal, A. K. (2013) · The FASEB Journal · doi:10.1096/fj.12-217257 · Cited by 186
Xu, J., Kulkarni, S. R., Donepudi, A. C., More, V. R., & Slitt, A. L. (2012) · Diabetes · doi:10.2337/db11-1716 · Cited by 183
Tufekci, K. U., Civi Bayin, E., Genc, S., & Genc, K. (2011) · Parkinson's Disease · doi:10.4061/2011/314082 · Cited by 182
Cheng, X., Siow, R. C. M., & Mann, G. E. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3283 · Cited by 181
Sussan, T. E., Jun, J., Thimmulappa, R., Bedja, D., Antero, M., Gabrielson, K. L., Polotsky, V. Y., & Biswal, S. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003791 · Cited by 179
The Nrf2-Keap1-ARE Signaling Pathway: The Regulation and Dual Function of Nrf2 in Cancer
Zhang, D. D. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3301 · Cited by 178
Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra
Muiswinkel, F. L. V., de Vos, R. A. I., Bol, J. G. J. M., Andringa, G., Steur, E. N. H. J., Ross, D., Siegel, D. M., & Drukarch, B. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.010 · Cited by 176
Binding Mode and Structure–Activity Relationships around Direct Inhibitors of the Nrf2–Keap1 Complex
Jnoff, E., Albrecht, C., Barker, J. J., Barker, O., Beaumont, E., Bromidge, S., Brookfield, F., Brooks, M., Bubert, C., Ceska, T., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300525 · Cited by 176
Keap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
The Keap1–Nrf2 Cell Defense Pathway – A Promising Therapeutic Target?
Copple, I. M. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-398339-8.00002-1 · Cited by 171
Monitoring Keap1–Nrf2 interactions in single live cells
Baird, L., Swift, S., Llères, D., & Dinkova-Kostova, A. T. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.03.004 · Cited by 167
Ungvari, Z., Bailey-Downs, L., Gautam, T., Jimenez, R., Losonczy, G., Zhang, C., Ballabh, P., Recchia, F. A., Wilkerson, D. C., Sonntag, W. E., et al. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00402.2010 · Cited by 162
Zhuang, C., Narayanapillai, S. C., Zhang, W., Sham, Y. Y., & Xing, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4017174 · Cited by 159
Reduction in Antioxidant Defenses may Contribute to Ochratoxin A Toxicity and Carcinogenicity
Cavin, C., Delatour, T., Marin‐Kuan, M., Holzhäuser, D., Higgins, L., Bezençon, C., Guignard, G., Junod, S., Richoz, J., Gremaud, E., et al. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfl169 · Cited by 156
Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction
Hancock, R., Bertrand, H. C., Tsujita, T., Naz, S., El-Bakry, A., Laoruchupong, J., Hayes, J. D., & Wells, G. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.486 · Cited by 151
The emerging role of redox-sensitive Nrf2–Keap1 pathway in diabetes
Bhakkiyalakshmi, E., Sireesh, D., Rajaguru, P., Paulmurugan, R., & Ramkumar, K. M. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.10.004 · Cited by 150
Sandford, A. J. (2002) · Thorax · doi:10.1136/thorax.57.8.736 · Cited by 148
The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice
Chen, T., Mou, Y., Tan, J., Wei, L., Qiao, Y., Wei, T., Xiang, P., Peng, S., Zhang, Y., Huang, Z., et al. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.01.011 · Cited by 147
Limonciel, A., & Jennings, P. (2014) · Toxins · doi:10.3390/toxins6010371 · Cited by 143
Lee, S., Lim, M., Kim, M., Yu, C., Yun, Y., Ahn, J., & Song, J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.038 · Cited by 133
Singh, A., Ling, G., Suhasini, A. N., Zhang, P., Yamamoto, M. P., Navas‐Acién, A., Cosgrove, G. P., Tuder, R. M., Kensler, T. W., Watson, W. H., et al. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.10.026 · Cited by 131
Small Molecule Inhibitors of the MDM2-p53 Interaction Discovered by Ensemble-Based Receptor Models
Bowman, A. L., Nikolovska‐Coleska, Z., Zhong, H. A., Wang, S., & Carlson, H. A. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073687x · Cited by 128
Bertrand, H. C., Schaap, M., Baird, L., Georgakopoulos, N., Fowkes, A., Thiollier, C., Kaatchi, H., Dinkova‐Kostova, A. T., & Wells, G. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00602 · Cited by 125
Vartanian, S., Ma, T. P., Lee, J., Haverty, P. M., Kirkpatrick, D. S., Yu, K., & Stokoe, D. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.055509 · Cited by 123
Reddy, N. M., Potteti, H. R., Mariani, T. J., Biswal, S. S., & Reddy, S. P. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0144oc · Cited by 121
Keap1: One stone kills three birds Nrf2, IKKβ and Bcl-2/Bcl-xL
Tian, H., Zhang, B., Di, J., Jiang, G., Chen, F., Li, H., Li, L., Pei, D., & Zheng, J. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.06.007 · Cited by 118
Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction
Steel, R., Cowan, J., Payerne, E., O'Connell, M. A., & Searcey, M. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300041g · Cited by 113
Tan, S. M., Sharma, A., Stefanovic, N., Yuen, D. Y. C., Karagiannis, T. C., Meyer, C. J., Ward, K. W., Cooper, M. E., & de Haan, J. B. (2014) · Diabetes · doi:10.2337/db13-1743 · Cited by 113
Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators
Jain, A. D., Potteti, H. R., Richardson, B. G., Kingsley, L. J., Luciano, J. P., Ryuzoji, A. F., Lee, H., Krunić, A., Mesecar, A. D., Reddy, S. P., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.049 · Cited by 111
An Exceptionally Potent Inducer of Cytoprotective Enzymes
Dinkova‐Kostova, A. T., Talalay, P., Sharkey, J., Zhang, Y., Holtzclaw, W. D., Wang, X. J., David, E., Schiavoni, K. H., Finlayson, S. D., Mierke, D. F., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.163485 · Cited by 107
Aleksunes, L. M., Reisman, S. A., Yeager, R. L., Goedken, M. J., & Klaassen, C. D. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162271 · Cited by 106
Inoyama, D., Chen, Y., Huang, X., Beamer, L. J., Kong, A. T., & Hu, L. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111430124 · Cited by 105
Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney
Reisman, S. A., Chertow, G. M., Hebbar, S., Vaziri, N. D., Ward, K. W., & Meyer, C. J. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050457 · Cited by 104
Winkel, A. F., Engel, C. K., Margerie, D., Kannt, A., Szillat, H., Glombik, H., Kallus, C., Ruf, S. G., Güssregen, S., Riedel, J., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.678136 · Cited by 104
Tarumoto, T., Nagai, T., Ohmine, K., Miyoshi, T., Nakamura, M., Kondo, T., Mitsugi, K., Nakano, S., Muroi, K., Komatsu, N., et al. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.01.007 · Cited by 97
A Small Molecule Inhibits Deregulated NRF2 Transcriptional Activity in Cancer
Bollong, M. J., Yun, H., Sherwood, L., Woods, A. K., Lairson, L. L., & Schultz, P. G. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00448 · Cited by 96
Jiang, Z., Xu, L., Lu, M., Chen, Z., Yuan, Z., Xu, X., Guo, X., Zhang, X., Sun, H.-P., & You, Q. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00185 · Cited by 94
Self-citationHübner, R., Schwartz, J. D., De, B. P., Ferris, B., Omberg, L., Mezey, J. G., Hackett, N. R., & Crystal, R. G. (2009) · Molecular Medicine · doi:10.2119/molmed.2008.00130 · Cited by 93
Bitar, M. S., & Al‐Mulla, F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00047.2011 · Cited by 91
Chen, Y., Inoyama, D., Kong, A. T., Beamer, L. J., & Hu, L. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01240.x · Cited by 87
Boesch, C., Łoboda, A., Józkowicz, A., Huebbe, P., Blank, R., Wolffram, S., Dulak, J., & Rimbach, G. H. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.04.023 · Cited by 87
Dimethyl Fumarate Modulation of Immune and Antioxidant Responses: Application to HIV Therapy
Gill, A. J., & Kolson, D. L. (2013) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2013007247 · Cited by 86
Peptide and small molecule inhibitors of the Keap1–Nrf2 protein–protein interaction
Wells, G. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150051 · Cited by 82
Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway
Richardson, B. G., Jain, A. D., Speltz, T. E., & Moore, T. W. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.019 · Cited by 80
Decline in DJ-1 and Decreased Nuclear Translocation of Nrf2 in Fuchs Endothelial Corneal Dystrophy
Bitar, M. S., Cai-ling, L., Ziaei, A., Chen, Y., Schmedt, T., & Jurkunas, U. V. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10119 · Cited by 80
Harada, N., Ito, K., Hosoya, T., Mimura, J., Maruyama, A., Noguchi, N., Yagami, K.-I., Morito, N., Takahashi, S., Maher, J. M., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.001 · Cited by 75
Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction
Adenuga, D., Caito, S. W., Yao, H., Sundar, I. K., Hwang, J., Chung, S., & Rahman, I. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.054 · Cited by 73
Reddy, N. M., Vegiraju, S., Yates, M. S., Kleeberger, S. R., Hassoun, P. M., Yamamoto, M. P., Liby, K. T., Sporn, M. B., Kensler, T. W., & Reddy, S. P. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200905-0670oc · Cited by 70
Ochratoxin A impairs Nrf2‐dependent gene expression in porcine kidney tubulus cells
Boesch, C., Wagner, A. E., Graeser, A.-C., Hundhausen, C., Wolffram, S., & Rimbach, G. H. (2008) · Journal of Animal Physiology and Animal Nutrition · doi:10.1111/j.1439-0396.2008.00838.x · Cited by 70
Zhuang, C., Miao, Z., Sheng, C., & Zhang, W. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140217104648 · Cited by 68
Zheng, S., Laxmi, Y. R. S., David, E., Dinkova‐Kostova, A. T., Shiavoni, K. H., Ren, Y., Zheng, Y., Isaac, T., Bumeister, R., Ojima, I., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003922 · Cited by 65
Wang, X., & Hai, C. (2011) · Mini-Reviews in Medical Chemistry · doi:10.2174/138955711797247761 · Cited by 63
Diffusion dynamics of the Keap1–Cullin3 interaction in single live cells
Baird, L., & Dinkova‐Kostova, A. T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.065 · Cited by 60
Sun, H.-P., Jiang, Z., Zhang, M.-Y., Lu, M., Yang, T., Pan, Y., Huang, H., Zhang, X., & You, Q. (2013) · MedChemComm · doi:10.1039/c3md00240c · Cited by 59
Self-citationChin, M. P., Lee, C.-Y. I., Chuang, J.-C., Bumeister, R., Wigley, W. C., Sonis, S. T., Ward, K. W., & Meyer, C. J. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00387.2012 · Cited by 58
Keap1–Nrf2 signalling in pancreatic cancer
Hayes, A. J., Skouras, C., Haugk, B., & Charnley, R. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.06.017 · Cited by 57
Binding thermodynamics and kinetics guided optimization of potent Keap1–Nrf2 peptide inhibitors
Lu, M.-C., Chen, Z.-Y., Wang, Y.-L., Jiang, Y.-L., Yuan, Z.-W., You, Q.-D., & Jiang, Z.-Y. (2015) · RSC Advances · doi:10.1039/c5ra16262a · Cited by 55
Self-citationIntegrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney
Shelton, L. M., Lister, A., Walsh, J., Jenkins, R. E., Wong, M. H. L., Rowe, C., Ricci, E., Ressel, L., Fang, Y., Demougin, P., et al. (2015) · Kidney International · doi:10.1038/ki.2015.286 · Cited by 53
Xu, L., Zhu, J., Xu, X., Zhu, J., Li, L., Xi, M., Jiang, Z., Zhang, M.-Y., Liu, F., Lu, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00170 · Cited by 51
Self-citationBaicalein modulates Nrf2/Keap1 system in both Keap1-dependent and Keap1-independent mechanisms
Qin, S., Deng, F., Wu, W., Jiang, L., Yamashiro, T., Yano, S., & Hou, D. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.03.011 · Cited by 51
Jiang, Z., Chu, H., Xi, M., Yang, T., Jia, J.-M., Huang, J., Guo, X., Zhang, X., You, Q., & Sun, H.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075076 · Cited by 51
Self-citationTopical Application of Ochratoxin A Causes DNA Damage and Tumor Initiation in Mouse Skin
Kumar, R., Ansari, K. M., Chaudhari, B. P., Dhawan, A., Dwivedi, P. D., Jain, S. K., & Das, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047280 · Cited by 48
You, R., Long, W., Lai, Z., Sha, L., Wu, K. C., Yu, X., Lai, Y., Ji, H., Huang, Z., & Zhang, Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301652t · Cited by 47
Conserved solvent and side-chain interactions in the 1.35 Å structure of the Kelch domain of Keap1
Beamer, L. J., Li, X., Bottoms, C. A., & Hannink, M. (2005) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905022626 · Cited by 42
Xi, M., Jia, J.-M., Sun, H.-P., Sun, Z., Jiang, J., Wang, Y., Zhang, M., Zhu, J., Xu, L., Jiang, Z., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400944k · Cited by 42
Self-citationSatoh, M., Saburi, H., Tanaka, T. U., Matsuura, Y., Naitow, H., Shimozono, R., Yamamoto, N., Inoue, H., Nakamura, N., Yoshizawa, Y., et al. (2015) · FEBS Open Bio · doi:10.1016/j.fob.2015.06.011 · Cited by 36
The Extinguished BEACON of Bardoxolone: Not a Monday Morning Quarterback Story
Tayek, J. A., & Kalantar‐Zadeh, K. (2013) · American Journal of Nephrology · doi:10.1159/000346950 · Cited by 36
Cullin3 - BTB Interface: A Novel Target for Stapled Peptides
de Paola, I., Pirone, L., Palmieri, M., Balasco, N., Esposito, L., Russo, L., Mazzà, D., Marcotullio, L. D., Gaetano, S. D., Malgieri, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121149 · Cited by 36
Jin, W., Wang, H., Ji, Y., Zhu, L., Yan, W. X., Qiao, L., & Hongxia, Y. (2009) · Experimental Biology and Medicine · doi:10.3181/0807-rm-232 · Cited by 34
Hörer, S., Reinert, D. J., Ostmann, K., Hoevels, Y., & Nar, H. (2013) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s174430911301124x · Cited by 32
Jiang, Z., Xu, L., Lu, M., Pan, Y., Huang, H., Zhang, X., Sun, H.-P., & You, Q. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9799-y · Cited by 29
Self-citationActivation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor
Wen, X., Thorne, G., Hu, L., Joy, M. S., & Aleksunes, L. M. (2015) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21693 · Cited by 27
Guntas, G., Lewis, S. M., Mulvaney, K. M., Cloer, E. W., Tripathy, A., Lane, T. R., Major, M. B., & Kuhlman, B. A. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv055 · Cited by 26
Reviving the promise of transcription factor Nrf2-based therapeutics for kidney diseases
Noel, S., Hamad, A. R. A., & Rabb, H. (2015) · Kidney International · doi:10.1038/ki.2015.328 · Cited by 26
Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway
Schneekloth, J. S., & Crews, C. M. (2011) · Current Drug Targets · doi:10.2174/138945011798109491 · Cited by 21
Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Kern, J. T., Hannink, M., & Hess, J. F. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607780906825 · Cited by 17
Cited by
Nrf2-Keap1 signaling in oxidative and reductive stress
Bellezza, I., Giambanco, I., Minelli, A., & Donato, R. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.02.010 · Cited by 2,053
Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation
Lu, Y., Li, Z., Zhang, S., Zhang, T., Liu, Y., & Zhang, L. (2023) · Theranostics · doi:10.7150/thno.79876 · Cited by 685
Understanding mechanisms of antioxidant action in health and disease
Halliwell, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00645-4 · Cited by 629
Wang, X., Chen, X., Zhou, W., Men, H., Bao, T., Sun, Y., Wang, Q., Tan, Y., Keller, B. B., Tong, Q., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.005 · Cited by 510
Nrf2/Keap1/ARE signaling: Towards specific regulation
Ulasov, A. V., Rosenkranz, A. A., Georgiev, G. P., & Sobolev, A. S. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120111 · Cited by 508
Metadata
- Authors
- Lu, M., Ji, J., Jiang, Z., & You, Q.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2016-05-18
- Volume
- 36
- Issue
- 5
- Pages
- 924-963
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2401030213
- Cited by
- 790
- References
- 202
- FWCI
- 26.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.